pharmaphorum

NOVEMBER 1, 2021

Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in August at 1.43 million yen (around $12,500) per dose, according to a Pharma Japan report.

Genetic Engineering 122

Genetic Engineering Clinical Trials Clinical Trials Trials 122

pharmaphorum

AUGUST 23, 2021

The vaccine may be a latecomer to the COVID-19 vaccine arsenal, but its approval signals the potential of DNA vaccines and is a boost to companies working in this space. The company also says that it can update the vaccine very easily to deal with mutations in the virus.

DNA 98

DNA Vaccine Vaccination Genetic Engineering 98

pharmaphorum

FEBRUARY 18, 2021

Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

XTalks

AUGUST 17, 2020

A growing area in the immunotherapy space is the development of biological modulators, which are genetically engineered proteins that target specific components of the immune system.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

DECEMBER 3, 2024

From blockbuster drugs like Ozempic to foundational treatments like insulin, these therapies showcase the diverse strategies used by pharma companies to meet the needs of a rapidly growing market. The first genetically engineered human insulin , Humulin , was introduced in 1982.

Sales 105

Sales Insulin FDA Approval Drugs 105